NEFL and multiple system atrophy: Until biomarkers that provide definitive in vivo proof of MSA pathology, such as seeding assays and skin biopsies, become reliable and widely accessible, biomarkers like NfL in combination with other biomarkers such as MRI imaging and MIBG scintigraphy may be utilized to facilitate the differential diagnosis of MSA from PD.